Robert Latek

Boehringer Ingelheim (United States) — United States

Medicine · Health Sciences

17h-index9.4kcitations42works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(14), Glioma Diagnosis and Treatment(12), Brain Metastases and Treatment(5), T-cell and B-cell Immunology(3), Protein Kinase Regulation and GTPase Signaling(3)

Publications42 total

A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors.
Journal of Clinical Oncology·2024
1030P Phase I, first-in-human trial evaluating the STING agonist BI 1387446 alone and in combination with ezabenlimab in solid tumors
Annals of Oncology·2023· 8 citedOpen Access
626 Trial in progress: an intravenously administered second-generation STING agonist, BI 1703880 with a novel lead-in design in combination with ezabenlimab
Regular and Young Investigator Award Abstracts·2022· 2 citedOpen Access
287 Safety and antitumor activity of indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts·2020· 3 citedOpen Access
Abstract CT238: An open-label, phase 1 study of IDO inhibitor KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic urothelial carcinoma
Cancer Research·2020· 1 cited
First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.
Journal of Clinical Oncology·2018· 13 cited
Development of a Molecular Signature to Monitor Pharmacodynamic Responses Mediated by In Vivo Administration of Glucocorticoids
Arthritis & Rheumatology·2018· 24 citedOpen Access
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
Neuro-Oncology·2017· 478 citedOpen Access
Histopathologic review of suspected disease progression in patients with recurrent glioblastoma (GBM) receiving nivolumab ± ipilimumab: CheckMate 143.
Journal of Clinical Oncology·2017· 2 cited
ATIM-16. NIVOLUMAB COMBINED WITH RADIOTHERAPY WITH OR WITHOUT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: RESULTS FROM PHASE 1 SAFETY COHORTS IN CHECKMATE 143
Neuro-Oncology·2016· 9 citedOpen Access
A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.
Journal of Clinical Oncology·2016· 52 cited
Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.
Journal of Clinical Oncology·2016· 42 cited
Challenges in the Imaging of Response and Progression During Treatment with Immune Checkpoint Inhibitors for Glioblastoma: Insights from Advanced Neuro-Imaging (P4.251)
Neurology·2016
CBM-06IMMUNE BIOMARKER RESULTS FROM A TRIAL OF NIVOLUMAB ± IPILIMUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE-143
Neuro-Oncology·2015· 1 citedOpen Access
CBM-04PD-1 EXPRESSION IDENTIFIES EXHAUSTED TUMOR INFILTRATING REGULATORY T CELLS IN GLIOBLASTOMA
Neuro-Oncology·2015Open Access
NIMG-16PSEUDOPROGRESSION AND IMMUNOTHERAPY IN GLIOBLASTOMA: A CASE SERIES FROM COHORT 1 OF CHECKMATE-143 (NCT02017717)
Neuro-Oncology·2015Open Access
QOL-07DESCRIPTION OF CLINICAL AND PATIENT REPORTED OUTCOMES ASSESSMENTS FROM A PHASE 3, MULTICENTER, RANDOMIZED TRIAL EVALUATING NIVOLUMAB MONOTHERAPY VERSUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA: CHECKMATE-143
Neuro-Oncology·2015Open Access
NIMG-18EVALUATING TUMOR PROGRESSION AND IMMUNOLOGIC REACTIONS DURING IMMUNOTHERAPY: NEUROIMAGING OBSERVATIONS FROM A MULTICENTER STUDY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA (CHECKMATE-143)
Neuro-Oncology·2015Open Access
IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143
Neuro-Oncology·2015· 11 citedOpen Access
NIMG-17CENTRAL NEUROPATHOLOGY REVIEW TO ASSIST IN THE EVALUATION OF IMMUNE-RELATED TREATMENT CHANGES VERSUS DISEASE PROGRESSION IN CHECKMATE-143
Neuro-Oncology·2015Open Access
page 1 of 3Next →

Frequent Co-authors

Solmaz Sahebjam(12), Antonio Omuro(11), Michael Lim(10), Joachim M. Baehring(10), Timothy F. Cloughesy(10), David A. Reardon(10), Gordana Vlahovic(9), John H. Sampson(9), Vlad Coric(8), Alfredo Voloschin(6), Lewis C. Strauss(6), Ricardo Zwirtes(4), Prashni Paliwal(4), Robert Townsend(4), Do‐Hyung Kim(3), Dos D. Sarbassov(3), Siraj M. Ali(3), Hediye Erdjument‐Bromage(3), Paul Tempst(3), David M. Sabatini(3)